Home | Emory University

Infectious Diseases Clinical Research Consortium (IDCRC)

Infectious Diseases Clinical Research Consortium

Slide 1:
Slide 2:
Slide 3:

The Infectious Diseases Clinical Research Consortium (IDCRC) and Vaccine and Treatment Evaluation Units (VTEUs) work in tandem with the National Institute of Allergy and Infectious Diseases (NIAID) as a coordinated national and global network of scientific experts working to develop and test vaccines and other therapies to combat infectious diseases.

NIH clinical trial evaluating Moderna COVID-19 variant vaccine begins

An investigational vaccine designed to protect against the B.1.351 SARS-CoV-2 variant has been administered as part of a new Phase 1 clinical trial supported by NIAID and IDCRC evaluating the vaccine candidate’s safety and immunogenicity in adult volunteers.

IDCRC News

COVID-19 Vaccine Appears Well-Tolerated and Effective in Developing Antibodies in Small Study of Older Adults

COVID-19 Prevention Network

The CoVPN was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network; the HIV Prevention Trials Network; the Infectious Diseases Clinical Research Consortium; and the AIDS Clinical Trials Group.

More about the CoVPN

COVID-19 Prevention Network launches two research studies evaluating monoclonal antibodies

IDCRC Sites Across the Nation

SUPPORT OF CLINICAL RESEARCH FOR 2019 NOVEL CORONAVIRUS (SARS-COV-2) & DISEASE (COVID-19)

The novel coronavirus 2019-nCoV, SARS-CoV-2, pandemic continues to expand and the IDCRC is working with NIAID to conduct clinical research into the treatment and prevention of infections (COVID-19) caused by this virus. What we know about COVID-19 and SARS-CoV-2 is constantly changing. To stay up-to-date on the most current information about how the epidemic is impacting the world, we recommend that you visit the following websites for reliable and accurate information.

View Resources

VTEU COVID-19 Trials

Infection and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Antibodies from infected and vaccinated individuals bind to the B.1.351 RBD, convalescent sera through eight months can neutralize the B.1.351 variant, and serum from vaccinated individuals retain neutralization against the B.1.351 variant.

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

A total of 1,033 patients underwent randomization (with 515 assigned to combination treatment and 518 to control). Patients receiving baricitinib had a median time to recovery of 7 days, as compared with 8 days with control, and a 30% higher odds of improvement in clinical status at day 15.

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

New England Journal of Medicine correspondence with the editor

Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination

Research Letter: Serum neutralizing antibodies rapidly appear after SARS-CoV-2 infection and vaccination and are maintained for several months.

About

The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.

IDCRC Active & Completed Studies